engleski

Immunocompetence in children with solid malignant tumors before, during and following anticancer therapy

THE NUMBER OF T AND B LYMPHOCYTES, THE REACTIVITY OF LYMPHOCYTES TO MITOGENES AND THE LEVEL OF IgG, IgA AND IgM IN PERIPHERAL BLOOD OF 91 CHILDREN WITH SOLID MALIGNANT TUMORS WAS INVESTIGATED. aLL TESTS WERE PWEFORMED BEFORE STARTING THE THERAPY, DURING THE THERAPY, AFTER ENDING THE THERAPY AND ONE YEAR SINCE THE END OF THE THERAPY. tHE CONTROL GROUP CONSISTED OF 60 HEALTHY AGE MATCHED CHILDREN. BEFORE STARTING THE THERAPY ALL INVESTIGATED PARAMETERS WERE FOUND LOWER IN THE GROUP OF PATIENTS THAN IN THE GROUP OF HEALTHY CHILDREN BUT STATISTICALLY SIGNIFICANT DIFFERENCES WAS NOT REACHED. tHERE WAS STATISTICALLY SIGNIFICANT DIFFERENCES OBSERVED IN ABOVE MENTIONED IMMUNOLOGICAL PARAMETERS BETWEEN THE PATIENTS WITH METASTASES AND RECRUDESCENCE AND THOSE WITHOUT METASTASES AND RECRUDESCENCE. ALSO NO STATISTICAL SIGNIFICANCE IN THOSE PARAMETERS WAS PROVED COMPARING THE CHILDREN WHO HAVE SURVIVED AND THOSE WHO DIED DURING THE FIVE YEARS OF OUR INVESTIGATION. hOWEVER, DURING THE THERAPY AND RECONVALESCENCE PERIOD, SIGNIFICANT DIFFERENCES IN ALL INVESTIGATED IMMUNOLOGICAL PARAMETERS BETWEEN THE CHILDREN WHO HAVE SURVIVED AND THOSE WHO HAVE DIED DURING THE FIVE YEARS OF FOLLOWING UP WAS FOUND. NAMELY, ANTICANCER THERAPY CAUSED SIGNIFICANT IMMUNOSUPRESSION IN BOTH GROUPS OF PATIENTS. tHIS EFFECT WAS MUCH MORE PRONUNCED IN THE GROUP OF PATIENTS WHO HAVE DIED. aLREADY AT THE END OF THE THERAPY, AND ESPECIALLY AFTER THE THERAPY HAS BEEN FINISHED, GRADUAL IMMUNOLOGICAL RECOVERY IS OBSERVED WITH THOSE WHO HAVE SURVIVED, UNTIL FINALLY REACHING THE NORMAL VALUES. tHIS WAS NOT THE CASE WITH THE GROUP OF PATIENTS WHO DIED. IN THIS GROUP THE DECLINE OF CELLULAR IMMUNOLOGICAL RECOVERY CONTINUED EVEN ONE YEAR AFTER THE THERAPY WAS FINISHED. aT THE SAME TIME THE LEVEL OF iGa, iGg AND iGm WAS INCREASED. oUR RESULTS SHOW THAT DETERMINATION OF INVESTIGATED IMMUNOLOGICAL PARAMETERS BEFORE STATRING THE THERAPY, IN CHILDREN WITH SOLID MALIGNANT TUMORS, HAS NO PROGNOSTIC VALUE. hOWEVER, DURING THE THERAPY, IT IS POSSIBLE TO PREDICT FURTHER COURSE OF THE DISEASE AND ITS FINAL ISSUE BASED ON THESE PARAMETERS. wE PRESUMED THAT IT WILL BE POSSIBLE , THROUGH OBSERVATION OF IMMUNOLOGICAL CHANGES DURING THE THERAPY, TO MODIFY THE THERAPEUTICAL PROTOCOL WITH THE AIM OF OBTAINING BETTER FINAL RESULTS.

nije evidentirano

nije evidentirano